The Real Chemistry Podcast

In this episode, Suzanne Jacobs, Group President of Medical at Real Chemistry, and Trina Stonner, President of Avant Healthcare, discuss Real Chemistry’s newly announced acquisition of Avant Healthcare, how the two companies came together and have similar ethos of supporting physicians in advancing patient care, and how the future of medical communications will involve a combination of data, creativity, AI, and human expertise. 

It's time to talk about cancer prevention and early detection. Join us as we explore the importance of early detection and prevention in the fight against cancer with Dr. Karen Knudsen, CEO of the American Cancer Society, and Jim Weiss, Founder and Chairman at Real Chemistry. Tune in to learn about the role of the American Cancer Society in research, advocacy and patient support, the importance of genetic testing in understanding cancer risk and the future of cancer testing and the role of AI.

Listen to our latest podcast with Peter Lee, Corporate Vice President, Microsoft Research & Incubations, and Brandon Pletsch, Practice Leader of Scientific Visualization at Real Chemistry, to learn about the applications and implications of generative AI, specifically GPT-4, in healthcare and other fields. They explore public perceptions of AI, its potential benefits and risks, the importance of ethical considerations and regulatory guidelines, and the concept of equitable access to AI in healthcare. Check out the episode to gain insight into how AI can revolutionize fields outside of human language and thought.

In this episode, Ajit Singh, PhD, Managing Director and General Partner at Artiman Ventures, shares his insights on various aspects of healthcare, his approach to leadership and decision-making and his thoughts on the future of healthcare. From AI to oncology to neuro technology, Ajit covers it all.

Learn more about the inspiring journey of Jason Gardner, Head of Medical at Real Chemistry, and his views on AI and DE&I in healthcare. From his father's struggle with multiple sclerosis to his strategic approach to medical communications, Jason shares his unique perspectives on how diverse thinking and experiences can bring value to the healthcare industry.

In this episode, National Pharmaceutical Council (NPC) President and CEO John O'Brien, PharmD, MPH, joins Real Chemistry’s Founder and Chairman, Jim Weiss, to discuss the pharmaceutical industry, the value assessment of medicines, the role of government in drug pricing and the importance of research in healthcare policy. Tune in to get the latest insights on the lack of clarity in government guidelines, the hostile environment for the pharmaceutical industry, the shift in benefits and the rise in patient costs, and the need for more transparency and value-based care.

Misinformation in the digital age is a complex problem, but it can be addressed. In this episode, Dr. Geeta Nayyar, former Chief Medical Officer at Salesforce and AT&T, discusses her book, Dead Wrong, and the role of artificial intelligence in healthcare. Tune in to learn more about the importance of trust in the healthcare industry, the role of life sciences companies in combating misinformation and the necessity of health literacy and prevention. 

In this episode, Javeria Shahab, President of Medical Education at 21GRAMS, a part of Real Chemistry, discusses the challenges and changes in the medical education industry, building effective teams and the importance of empathy in healthcare communications. Get an insider's look into the industry and hear Javeria's advice for those looking to break into the field.

In this episode, Dr. Sue Desmond-Hellmann, Member of President Biden’s Council of Advisors on Science and Technology and former CEO of the Bill & Melinda Gates Foundation, Mike Huckman, Global Practice Leader of Executive Communications at Real Chemistry, and Jim Weiss, Founder and Chairman at Real Chemistry, discuss the importance of vaccination, the evolution of cancer treatments and the challenges of clinical trials. They also highlight the need for diverse representation in clinical trials, the implications of the Inflation Reduction Act on the pharmaceutical industry and the influence of science in public health and policymaking.

In this episode, Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), Dr. Jay Bradner, FNIH board member and former President of the Novartis Institutes for Biomedical Research, and Jim Weiss, Founder and Chairman at Real Chemistry and FNIH board member, discuss the power of collaboration, how trust in science is essential for progress, emerging areas in medicine and the challenges of the current healthcare landscape. Listen to the full episode to gain valuable insights and to learn how FNIH is pioneering public-private partnerships to tackle complex health issues.